International Journal of Advanced Research in Biological Sciences
ISSN: 2348-8069
www.ijarbs.com
DOI: 10.22192/ijarbs Coden: IJARQG(USA) Volume 4, Issue 12 - 2017

Review Article

DOI: http://dx.doi.org/10.22192/ijarbs.2017.04.12.016

A Review study on "The effect of Metoprolol and Losartan on Isoprenaline Induced Heart Failure Mice".

Akriti Nepal*, Chen Ding-Ding*[1], Sufia Yasmeen[2], Nirmala Koju[3], Muhammad Abbas[4], Cao Teng-Li[5], Zhang Xiu Xiu[6]

Masters in Pharmacology, Basic Medicine and Clinical Pharmacy Department, China Pharmaceutical University, Nanjing, China (*, 3, 5,6)
Masters in Clinical Pharmacy, Basic Medicine and Clinical Pharmacy Department, China Pharmaceutical University, Nanjing, China (2, 4)
Corresponding Author: Professor **Chen Ding-Ding**
Nanjing, China
Contact No:- 13805179968
Email id: -*chdd@cpu.edu.cn*

Abstract

Heart failure, the one, and only cardiovascular disease is the primary cause of mortality and morbidity with increasing incidence and possess a considerable economic burden. The abrasions seen after Isoprenaline treatment are even more severe than those induced by epinephrine or norepinephrine. This severeness implies that the administration of Isoprenaline diminishes the efficacy of cardiac muscle cells and causes complex biochemical and structural alterations leading to cell damage and necrosis. Moreover, the abrasions demonstrated that ACE inhibitors reduce blood pressure, enhance left ventricular hypertrophy, decrease morbidity and mortality in cardiac failure, and inhibit progression to explicit cardiac failure in patients with depressed ventricular function or myocardial infarction. On the other hand, Beta-blockers decrease heart rate, lower blood pressure and cardiac contractility prominent to diminished oxygen consumption which may, in turn, stimulate the metoprolol-induced enhancement in function and structure.

Keywords: Heart Failure (HF); Cardiovascular Disease (CVD); Necrosis; Myocardial Infarction (MI),Left Ventricular Hypertrophy; Scar formation.

Introduction

One of the primary cause of mortality and morbidityin today's linguistic context lead-in to Heart Failure (HF)[1].Congestive heart failure (referred to as HF) is a severe cardiovascular disease with increasing incidence and preponderance. Despite recent progress inHF therapy, mortality remains high [2]. Therefore, new therapeutic remedies or advance are needed to decrease morbidity and mortality in heart failure patients. It is a well-known fact that it is a developed end-stage of various cardiac disorder, and the common final outcome is cardiac overload or myocardial harm leadingto thedeficiency in supplying blood to meet the metabolic needs of the body. The most projecting device characteristic of heart failure are impairment of active relaxation and contraction of the left ventricle, ventricular remodeling, ventricular hypertrophy, and

reduced ejection fraction [3].HF is unvaryinglyconnected with cardiac hypertrophy, and the modifications in the cardiac remodeling (i.e.shape and size of cadiocyte) are time and againreflected to explain cardiac dysfunction in HF. Cardiovascular disease is the prominent cause of death in both men and women equally[4]. Unexpected cardiac arrest causes many of these deaths. Population-based information of emergency brake medical services 'experience from the United States of America springiness survival evaluates approximately 8%[4]. The adrenergic receptors in the heartare stimulated by catecholamine whichis mainly the a-adrenoceptors and b-adrenoceptors (b1 and b2); after all, the b2-adrenoceptors are found chiefly in extra cardiac spots, such as arterioles, where Dilation occurs.

With this in mind, traditional remedies for congestive heart failure (CHF), such as diuretics, digitalis, and vasodilators, assists to control indications, however, excluding therapy for hydralazine plus nitrates, they have not shown the beneficial effect on survival. The use of beta-blockades in patients especially with HF has been debatable and conventionally contraindicated, for the reason of their negative inotropic effects. Conversely, in a latest randomized trial, beta-adrenergic receptor blockers consume to decrease total mortality and the occurrence of unexpected deaths in patients with Heart failure (HF) [5], along with enhanced ejection fraction, systemic pressure, and exercise capacity [6]. For the time being, the verifiedadvantage of angiotensin-converting enzyme (ACE) inhibitors for remodeling total mortality was demonstrated by the outcomes of the CONSENSUS [7], SOLVD [8], V-HeFTII trial [9], and Pfeffer study [7], and the obstruction of progressive :left ventricular dilatation was shown by SOLVD treatment trials. Meanwhile, combination therapy is recurrently signed in a clinical setting, there are limited published reports on the effects of a combination of an ACE inhibitor and a beta-adrenergic blocker in HF. HF has been effectively induced in mice by injection of encephalomyocarditis (EMC) virus, which produces abrasionsrelated to those connected with dilated cardiomyopathy in the chronic stage [10, 11].

A well-known fact is that epinephrine, norepinephrine, and Isoprenaline induce cardiac hypertrophy and/or myocardial abrasions[12-15]. The abrasions induced by epinephrine, norepinephrine, and Isoprenalinewere partially same, yet the abrasions were still seen after Isoprenalinetreatment which was even more serious than those induced by epinephrine or norepinephrine[16, 17]. Indeed, Isoprenalineinitiated were found to be 29 to 72 times more effective ininducing myocardial abrasions of identical severity than epinephrine or nor-epinephrine. Beta blockers are the keystone treatment of HF (shown in Figure 1)[18]. Beta-blockers inconsistentlyinverse these modifications, contracting sympathetic drive and proliferating β-receptor susceptibility. Up-to-the minute HF with conserved LVEF (HFpEF),[19, 20] plasma catecholamine concentrations are not elevated; however, even in the lack of epicardial coronary artery disease HFpEF patients do not generally have an increase in EF in reaction to exercise or β-adrenergic stimulation,[20] symptomatic of β-adrenergic receptor desensitization[21].

The most important achievement of the angiotensin converting enzyme (ACE) inhibitors in the medication of hypertension and CVD has directed theattention in substitutemethods to block the renin-angiotensin system2 [22, 23](shown in figure 2). ACE inhibitors reduce blood pressure, enhance left ventricular hypertrophy, decrease morbidity and mortality in cardiac failure, and inhibit progression to explicit cardiac failure in patients with depressed ventricular function or myocardial infarction.' [22]Additionally, they have advantageous effects in diabetic and non-diabetic nephropathy. In Comparison with added standard HF medications such as angiotensin-converting enzyme inhibitors (ACEI) and aldosterone antagonists, β-blockers frequently directed to a newconsiderableenhancement in EF and have an anti-ischemic effect, decreasing the possibility of unexpected cardiac death.[24] Here, we review the effect of β-blockers and ACE inhibitors permitting to the eminence of HF and the admissibility and ultimate dosage of different dose of β-blockers and ACE inhibitors (Metoprolol and Losartan) and recommended an optimumline of attack for treatment with them.



Figure No.1 .Mechanism of Beta-Blockers in heart Failure



Figure No.2. Renin angiotensin system bioenzymatic cascade and potential steps to block the system

Mechanism of Isoprenaline Induced – Cardiomyopathy

The current research indicates progressive ventricular remodeling in reaction to preliminary myocardial necrosis in ISO-treated rats/mice regardless of the occurrence of a light coronary transmission. Two weeks afterward of ISO administration, the myocardial injury was correlated with the proliferation of right atrial pressure, left ventricular filling pressure, LV hypertrophy, and left ventricular dilatation. Ventricular dilatation in the course of initial two weeks after ISO administration was the result of two distinctive procedures: (i) scar formation, and (ii) injury, or infarct expansion. The following part encapsulated a process of inconsistent thinning as well as dilatation of the intensely infarcted myocardium that initiate in the first 24 hours after infarction[25, 26]. Consequently, as with experimental myocardial infarction [27-29], indicative cardiomyocyte injury

primarily of the left ventricle is the preliminary contempt that gives spark to the progression of heart failure.

Another possible explanation is that administration of Isoprenaline diminishes the efficacy of cardiac muscle cells and induces complex biochemical and structural alterations that ultimately lead towards cell damage and necrosis[30]. Isoprenaline knows how to cause oxidative severe heart myocardium. Truthfully, this one was searched out that comparatively low and nonlethal doses of Isoprenaline can induce severe myocardial necrosis[31]. The severity of myocardial damage existed was associated towards the quantity of Isoprenaline administered and several commencing focal abrasions distressing single cells to large infarcts comprising significant portions of the myocardium. Isoprenaline remained set up to initiate apical abrasions and scattered focal necrosis [32].This one assumed that Isoprenaline-induced myocardial necrosis is associated with reformed myocardial energy cohort, which may be correlated in the direction of Ca2+ -overload. Ca2+ -influx afterward Isoprenaline in mice demonstrates two segments: a rapid procedure going on instantaneously, monitored by a delayed slower influx of Ca2+.

Even though extreme quantities of circulating catecholamines remain to induce cardiomyopathy, the mechanics are not visibly understood. It existed that equally high and low doses of Isoprenaline elevated the heart rate correspondingly. However, the cardiac abrasion– generating doses of Isoprenaline concluded a fall in blood pressure. It was put forward that the reduction in aortic blood pressure was such a step that a condensed coronary flow might be unuttered. Therefore, the inordinate injury to the myocardium by Isoprenaline as linked with epinephrine or norepinephrine was accredited to the theatrical hypotension. Many aspects, such as preceding myocardial damage, former Isoprenaline doses, or instigation of metabolic procedures were reflected to make available for cardiac muscle cells with remodeling to endure the increased oxygen demand as well as relative hypoxia induced by Isoprenaline[33]. An additional assumption is thoroughly associated to that of the coronary inadequacy of hemodynamic origin is that of a comparative including together direct metabolic actions in the cardiac muscle such as aspects secondary towards vascular and hemodynamic effects[34]. Histological variations in Isoprenaline – induced Cardiomyopathy remain in the primary consideration as deterioration and necrosis of myocardial fibre, accumulation of inflammatory cells for example leukocytes, interstitial edema, lipid droplet (fat deposition), and endocardial haemorrhage[32].

Clinical studies and Efficacy

In the technologically advanced world these days, heart failure is the cardiovascular disorder with the maximum impact on communal health resources[35]. Ideal therapy, which can slow the advancement of this disease, is grounded on effective inhibitors of the renin–angiotensin– aldosterone system. These inhibitors are known to be significant to the pathophysiology of heart failure. Effective inhibition of this structure needs a connection of agents to block individually three focal constituents: a beta-blocker; an aldosterone antagonist; and an ACE inhibitor and/or an ARB to block angiotensin II-mediated effect.

In experimental evaluation, the utmost comprehensively studied among ACE inhibitors, and Beta Blockers is Losartan and Metoprolol with different doses. The advantageous effects of beta-blockers on morbidity and mortality in HF through systolic dysfunction remained there and was well accepted in quite a lot of significant randomized controlled trials (RCTs). The efficacy of beta-blockers intended for heart failure patients with a well-preserved left ventricular systolic function has not been well validated. Dropping blood pressure, slowing down the heart rate and decreasing myocardial oxygen demand might have significant advantageous effects in these patients, particularly in people with ischemic heart failure and atrial fibrillation. On the other hand, currently, there is no direct indication of the clinical efficacy of beta-blockers further than the effects of additional classes of heart failure drugs in HF patients through a preserved left ventricular systolic function. Table 1 reveals the focal findings on the significant endpoints for individually, the utmost relevant clinical trials of beta-blockers in HF patients. Only the initial placebo-controlled trials of beta-blockers in HF was the Metoprolol in Dilated Cardiomyopathy (MDC) trial.In this trial, 383 patients with mild-to-moderate heart failure starting from idiopathic dilated cardiomyopathy remained randomized to either placebo or metoprolol at a dose of 5 mg twice daily and subsequently titrated to a target dose of 100–150 mg daily[36]. Metoprolol remained connected through 34% decrease in the composite primary endpoint of death or progression to heart transplantation.

With losartan, plasma renin, Ang I, and Ang II marked up without a substantial reduction in plasma aldosterone; unlike losartan, did not reduce plasma uric acid. Whether reactions to losartan are influenced by factors such as ethnicity, gender, and age is not known till now[22]. Nowadays in heart failure, angiotensin receptor antagonists consume more or less likely benefits over ACE inhibitors: in those transformed to an active metabolite, the moderate beginning of action might avoid first-dose hypotension; they will antagonize Ang II produced via non-ACE pathways, that may be increased in the diseased heart[37]. Losartan 50 mg every day had decreased blood pressure, systemic vascular resistance, pulmonary capillary wedge pressure, and heart rate in addition to had elevated the cardiac index. Remarkably, no methodical fluctuations in plasma renin, angiotensin, aldosterone, or noradrenaline were identified. The medication was well endured, even though about 10% turn out to be hypotensive with the first dose of 25 or 50 mg. To this point, losartan has been permitted merely for use in essential hypertension. The usual starting dose will be 50 mg once a day. No, any specific improvement was seen in increasing the dose more than 100mg/day. Losartan along with other angiotensin receptor antagonists have the beneficial effects of not initiating postural impact and tachycardia whereas cardiovascular reflexes are sustained. Additionally, they are lipid neutral and be able to be administered to hypertensive patients along with concomitant diseases, for example, chronic obstructive airways disease, asthma, peripheral vascular disease, diabetes, and depression that frequently bound the use of other classes of antihypertensive drugs.

Left ventricular remodeling remnants as an essential treatment target in patients afterward myocardial infarction and chronic heart failure[38].An Expanded indication has sustained the perception that advantageous effects of existing pharmacological treatments, such as beta-blockers, are, at a minimum in part, due to their effects on LV remodeling and dysfunction[39, 40]. Outlining possible applications and implications of the present study using mice model of coronary ligation is that beta-blocker metoprolol brings about useful structural remodeling and consequent enhancement of LV systolic function. However, ARB losartan had detrimental effects on LV remodeling in the course of improvement of post-infarction heart failure. Both treatments had no beneficial effect on the scar area, a trademark of late post-infarction remodeling, as revealed previously by others[41, 42]. Referring backward and forwards in the paper effect of metoprolol or losartan on CSCs afterward MI has not been reviewed earlier. The quantity of c-kit+ cells, conversely, was restricted in view of the range of myocardial damage by infarction, as well as the fluctuations in c-kit+cells may be an indication of a complete phenotypic variation caused by beta-blocker treatment in addition to or as a substitute of an individual regenerative process. Beta-blockers decrease heart rate, decrease blood pressure and cardiac contractility [43] prominent to diminished oxygen consumption which may, in turn, stimulate the metoprolol-induced enhancement in function and structure.

Table 1. Clinical trials of beta-blockers in patients with chronic heart failure

Study	Year	Patients	Beta-blocker tested	EF	Main findings on primary end point
MDC [13]	1993	383	Metoprolol vs placebo	<40%	34% reduction in ACM or progression to heart transplantation
CIBIS [19]	1994	641	Bisoprolol vs placebo	<40%	No significant difference in ACM
USCHFS [14–16]	1996	1094	Carvedilol vs placebo	≤35%	65% mortality reduction and 38% reduction in death or hospitalization for cardiovascular reasons
CIBIS II [18]	1999	2647	Bisoprolol vs placebo	≤35%	34% decrease in ACM
MERIT-HF [17]	2000	3991	Metoprolol vs placebo	≤40%	34% decrease in ACM and 19% reduction in ACM or ACH
BEST [21]	2001	2708	Bucindolol vs placebo	≤35%	No significant difference in death from any cause
CAPRICORN [22]	2001	1959	Carvedilol vs placebo	≤40%	23% reduction in ACM and no significant difference in ACM or cardiovascular hospital admission
COPERNICUS [20]	2002	2289	Carvedilol vs placebo	≤25%	35% decrease in ACM
COMET [23]	2003	3029	Carvedilol vs metoprolol	≤35%	17% reduction in ACM and no significant difference in ACM or ACH
SENIORS [24]	2005	2128	Nebivolol vs placebo	≤35%	14% proportional reduction in ACM or cardiovascular hospital admission
CIBIS III [26]	2005	1010	Bisoprolol	≤35%	'Bisoprolol first strategy' was non-inferior with regard to ACM or ACH in ITT, but not PP

a Abbreviations: MDC, Metoprolol in Dilated Cardiomyopathy; CIBIS II, Cardiac Insufficiency Bisoprolol Study; USCHFS, US Carvedilol HF Study; MERIT-HF, Metoprolol CR/ XL Randomized Intervention Trial in Congestive Heart Failure; BEST, Beta-Blocker Evaluation and Survival Trial; CAPRICORN, Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction; COPERNICUS, Carvedilol Prospective Randomized Cumulative Survival; COMET, Carvedilol or Metoprolol European Trial; ACM, all-cause mortality; ACH, all-cause hospitalization; ITT, intention to treat; PP, per protocol

Conclusion

The significant finding of the present study suggests that comparatively low and non-lethal doses of Isoprenaline can induce severe myocardial necrosis. Another possible explanation was, Isoprenaline persisted in set up to initiate apical abrasions and scattered focal necrosis leading to apoptosis. In experimental evaluation, the utmost comprehensively studied among ACE inhibitors, and Beta Blockers is Losartan and Metoprolol with different doses. Therefore, Beta-Blocker metoprolol brings about useful structural remodeling and consequent enhancement of LV systolic function. However, ARB losartan had detrimental effects on LV remodeling in the course of improvement of post-infarction heart failure. Both treatments had no beneficial effect on the scar area.

References

1. Thompson, K.A., et al., *Heart failure therapy: beyond the guidelines.* Journal of Cardiovascular Medicine, 2010. **11**(12): p. 919-927.
2. Zwieten, P.v. *Drug treatment of congestive heart failure*. in *Seminars in Cardiothoracic and Vascular Anesthesia*. 2003. Sage Publications Sage CA: Thousand Oaks, CA.
3. Johnson, F.L., *Pathophysiology and etiology of heart failure.* Cardiology clinics, 2014. **32**(1): p. 9-19.
4. Mathers, C., *The global burden of disease: 2004 update*. 2008: World Health Organization.
5. Anderson, J.L., et al., *A randomized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy.* The American journal of cardiology, 1985. **55**(4): p. 471-475.
6. Andersson, B., et al., *Exercise hemodynamics and myocardial metabolism during long-term beta-adrenergic blockade in severe heart failure.* Journal of the American College of Cardiology, 1991. **18**(4): p. 1059-1066.
7. Group, C.T.S., *Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).* New Engl J Med, 1987. **316**: p. 1429.
8. Investigators, S., *Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.* N Engl j Med, 1991. **1991**(325): p. 293-302.
9. Cohn, J.N., et al., *A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure.* New England Journal of Medicine, 1991. **325**(5): p. 303-310.
10. Matsumori, A. and C. Kawai, *An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus.* Circulation, 1982. **66**(2): p. 355-360.
11. Matsumori, A., C. Kawai, and S. Sawada, *Encephalomyocarditis Virus Myocarditis in Inbred Strains of Mice: Chronic Stage: THE 6th CONFERENCE ON PREVENTION FOR RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE.* Japanese circulation journal, 1982. **46**(11): p. 1192-1196.
12. Ziegler, K., *Uber die Wirkung intravenoser Adrenalininjektion auf das Gefassystem und ihre Beziehung zur Arteriosklerose.* Beitr Pathol Anat, 1905. **38**: p. 229.
13. Pearce, R.M., *Experimental myocarditis; a study of the histological changes following intravenous injections of adrenalin.* The Journal of experimental medicine, 1906. **8**(3): p. 400.
14. Rahmathulla, S.M., et al., *Effect of Tribulus terrestris (L.) on liver in Isoproterenol-Induced Myocardial Infarction.* International Journal of Research in Biochemistry and Biophysics, 2012. **2**(4): p. 10-12.
15. Rona, G., et al., *An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat.* AMA archives of pathology, 1959. **67**(4): p. 443-455.
16. Ošťádal, B., et al., *Structural and biochemical remodelling in catecholamine-induced cardiomyopathy: comparative and ontogenetic aspects.* Molecular and cellular biochemistry, 1995. **147**(1): p. 83-88.
17. Müller, E., *Histochemical studies on the experimental heart infarction in the rat.* Naunyn-Schmiedeberg's Archives of Pharmacology, 1966. **254**(5): p. 439-447.
18. Rienstra, M., et al., *Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis.* JACC: Heart Failure, 2013. **1**(1): p. 21-28.

19. Ueda, T., et al., *Left ventricular ejection fraction (EF) of 55% as cutoff for late transition from heart failure (HF) with preserved EF to HF with mildly reduced EF.* Circulation Journal, 2015. **79**(10): p. 2209-2215.
20. Phan, T.T., et al., *Impaired heart rate recovery and chronotropic incompetence in patients with heart failure with preserved ejection fraction.* Circulation: Heart Failure, 2009: p. CIRCHEARTFAILURE. 109.877720.
21. Borlaug, B.A., et al., *Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction.* Circulation, 2006. **114**(20): p. 2138-2147.
22. Johnston, C.I., *Angiotensin receptor antagonists: focus on losartan.* The Lancet, 1995. **346**(8987): p. 1403-1407.
23. Robertson, J., *Renin and the pathophysiology of renovascular hypertension.* The Renin-angiotensin system, 1993. **55**: p. 1-34.
24. McMurray, J., *V, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart.* Eur J Heart Fail, 2012. **14**(8): p. 803-69.
25. Hutchins, G.M. and B.H. Bulkley, *Infarct expansion versus extension: two different complications of acute myocardial infarction.* The American journal of cardiology, 1978. **41**(7): p. 1127-1132.
26. Eaton, L.W., et al., *Regional cardiac dilatation after acute myocardial infarction: recognition by two-dimensional echocardiography.* New England Journal of Medicine, 1979. **300**(2): p. 57-62.
27. Johns, T.N. and B.J. Olson, *Experimental myocardial infarction: I. A method of coronary occlusion in small animals.* Annals of surgery, 1954. **140**(5): p. 675.
28. Pfeffer, J.M., M.A. Pfeffer, and E. Braunwald, *Influence of chronic captopril therapy on the infarcted left ventricle of the rat.* Circulation research, 1985. **57**(1): p. 84-95.
29. Pfeffer, M.A., et al., *Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril.* Circulation, 1985. **72**(2): p. 406-412.
30. Chappel, C., et al., *Severe myocardial necrosis produced by isoproterenol in the rat.* Archives internationales de pharmacodynamie et de therapie, 1959. **122**: p. 123.
31. Rona, G., et al., *Myocardial lesions, circulatory and electrocardiographic changes produced by isoproterenol in the dog.* Revue canadienne de biologie/editee par l'Universite de Montreal, 1959. **18**(1): p. 83-94.
32. Mohan, P. and S. Bloom, *Lipolysis is an important determinant of isoproterenol-induced myocardial necrosis.* Cardiovascular Pathology, 1999. **8**(5): p. 255-261.
33. GHATS, W. and S. INDIA, *INTERNATIONAL RESEARCH JOURNAL OF PHARMACY.*
34. Bajusz, E., *The terminal electrolyte-shift mechanism in heart muscle; its significance in the pathogenesis and prevention of necrotizing cardiomyopathies*, in *Fundamental Aspects*. 1965, Karger Publishers. p. 274-322.
35. Cowie, M., et al., *The epidemiology of heart failure.* European heart journal, 1997. **18**(2): p. 208-225.
36. Waagstein, F., et al., *Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.* The Lancet, 1993. **342**(8885): p. 1441-1446.
37. Urata, H., et al., *Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart.* Journal of Clinical Investigation, 1993. **91**(4): p. 1269.
38. St John Sutton, M., *Left ventricular remodeling after myocardial infarction: pathophysiology and therapy.* Circulation, 2000. **101**: p. 2981-2988.
39. Assmus, B., et al., *Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure.* Circulation research, 2007. **100**(8): p. 1234-1241.
40. McMurray, J.J. and M.A. Pfeffer, *steady increase, age-adjusted rates of admission for heart failure seem to have reached a plateau, or even decreased.* Lancet, 2005. **365**: p. 1877-89.
41. Wei, S., L.T. Chow, and J.E. Sanderson, *Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction.* Journal of the American College of Cardiology, 2000. **36**(1): p. 276-281.

42. Jain, M., et al., *Angiotensin II receptor blockade attenuates the deleterious effects of exercise training on post-MI ventricular remodelling in rats.* Cardiovascular research, 2000. **46**(1): p. 66-72.

Access this Article in Online	
	Website: www.ijarbs.com
Quick Response Code	Subject: Pharmacology
DOI:10.22192/ijarbs.2017.04.12.016	

How to cite this article:
Akriti Nepal, Chen Ding-Ding, Sufia Yasmeen, Nirmala Koju, Muhammad Abbas, Cao Teng-Li, Zhang Xiu Xiu. (2017). A Review study on "The effect of Metoprolol and Losartan on Isoprenaline Induced Heart Failure Mice". Int. J. Adv. Res. Biol. Sci. 4(12): 158-165.
DOI: http://dx.doi.org/10.22192/ijarbs.2017.04.12.016